UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549



                                    FORM 8-K
                                 CURRENT REPORT



                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934



         Date of Report (Date of earliest event reported: July 9, 2003):



                            IGEN INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)



               Delaware                                 0-23252
    (State or other Jurisdiction of            (Commission File Number)
            Incorporation)

                                   94-2852543
                     ( I.R.S. Employer Identification No.)




                             16020 Industrial Drive
                          Gaithersburg, Maryland 20877
                     (Principal Executive Office) (Zip Code)



       Registrant's telephone number, including area code: (301) 869-9800

                             Exhibit Index on Page 4






Item 5.  Other Events

On July 9, 2003, IGEN International, Inc. ("IGEN") announced that the U.S. Court
of Appeals for the Fourth Circuit affirmed IGEN's right to terminate the License
and  Technology  Development  Agreement  dated as of  September  23,  1992  (the
"License  Agreement"),  between IGEN and Roche  Diagnostics  GmbH  ("Roche"),  a
division  of F.  Hoffman-LaRoche.  IGEN has  notified  Roche  that  the  License
Agreement has  terminated.  The Court of Appeals also  affirmed  IGEN's right to
certain improvements  developed by Roche under the License Agreement,  including
Roche's Elecsys(R) diagnostics product line.

In addition, the Court of Appeals reversed the portion of the judgment that held
Roche liable for unfair  competition,  thus  vacating the $400 million  punitive
damage  award  against  Roche.   The  ruling  also  reversed  $86.8  million  in
compensatory  damages  and left  intact  IGEN's  right to over  $18  million  in
compensatory damages for unpaid royalties, out-of-field-sales and withholding of
improvements.

Termination of the License  Agreement ends Roche's rights under the license from
IGEN to  manufacture,  market,  and sell  ORIGEN-based  products,  including its
Elecsys 1010 and 2010  instruments and assays.  In addition,  Roche is no longer
licensed to sell the Elecsys E170 product line,  which has been  integrated into
Roche's MODULAR ANALYTICS system.  This system couples together Roche's clinical
chemistry  systems  with the Elecsys  E170  immunoassay  systems and a series of
other  modules.  In  addition,  IGEN will  receive  specified  rights to certain
improvements  relating to the Elecsys  product line, as well as to certain other
improvements  licensed,  owned or developed by Roche,  including  PCR, a nucleic
acid amplification technology.

Also on July 9, 2003, IGEN filed patent  infringement  lawsuits against Roche in
the United  States and Germany to ensure that Roche ceases any further  sales of
products that incorporate IGEN's ORIGEN technology.  IGEN filed an action in the
U.S. District Court for the District of Maryland seeking a finding that Roche is
infringing  IGEN's  ORIGEN  patents,  as well  as a  preliminary  and  permanent
injunction  against  Roche's further  infringement  of those patents.  A similar
lawsuit was simultaneously filed in Germany.

A copy of the opinion  can be found on the website of the U.S.  Court of Appeals
for the Fourth Circuit at http://pacer.ca4.uscourts.gov/opinion.pdf/021537.P.pdf

IGEN also  intends to post a copy of the opinion on its website at  www.igen.com
and will file it with the SEC as soon as reasonably practicable.

Cautionary Note About Forward-Looking Statements

This Form 8-K  contains  forward-looking  statements  within the  meaning of the
"safe harbor" provision of the Private Securities Litigation Reform Act of 1995.
All statements  that are not statements of historical  fact are  forward-looking
statements.  The words "may," "should," "will," "expect," "could," "anticipate,"
"believe,"  "estimate,"  "plan," "intend" and similar expressions have been used
to identify certain of the forward-looking  statements in this Form 8-K. We have
based these  forward-looking  statements on management's  current  expectations,
estimates  and   projections  and  they  are  subject  to  a  number  of  risks,
uncertainties  and  assumptions  which  could  cause  actual  results  to differ
materially from those described in the forward-looking statements. The following
factors are among those that may cause actual results to differ  materially from
our  forward-looking  statements:  the outcome of the Roche  litigation  and our
relationship  with Roche  Diagnostics GmbH; our ability to develop and introduce
new or  enhanced  products;  our  ability  to enter into new  collaborations  on
favorable  terms,  if at all;  our  ability to expand the  commercialization  of
existing products; our ability to expand our manufacturing  capabilities or find
a suitable  manufacturer on acceptable terms or in a timely manner;  our ability
to develop our selling,  marketing and  distribution  capabilities;  our and our
licensees'  ability to obtain FDA and other  governmental  approvals for our and
their  clinical  testing  products;  the ability of our licensees to effectively
develop and market products based on the technology we license to them; domestic
and foreign  governmental  and public policy  changes,  particularly  related to
health  care  costs,  that may  affect new  investments  and  purchases  made by
customers;  availability of financing and financial resources in the amounts, at
the times and on the terms  required  to  support  our  future  business;  rapid
technological  developments in each of our markets and our ability to respond to
those changes in a timely,  cost-effective  manner;  protection  and validity of
patent and other intellectual  property rights; and changes in general economic,
business and industry conditions.  These and other risk factors are discussed in
IGEN's annual report on Form 10-K for the year ended March 31, 2003,  filed with
the  Securities  and  Exchange  Commission  (SEC) and  available at the Investor
Relations  section of IGEN's web site at  www.igen.com  or the SEC's web site at
www.sec.gov.  IGEN  disclaims  any intent or  obligation  to update any  forward
looking statements.

Item 9.  Regulation FD Disclosure

On July 9, 2003,  IGEN  issued the press  release  attached  to this Form 8-K as
Exhibit  99.1,  announcing  the  decision  of the U.S.  Court of Appeals for the
Fourth Circuit in IGEN's litigation with Roche. The information provided in Item
9 of  this  Form  8-K,  including  Exhibit  99.1,  shall  not  be  deemed  to be
incorporated  by reference into IGEN's filings with the SEC under the Securities
Act of 1933.







                                  EXHIBIT INDEX

Exhibit No.    Description
99.1           Press Release issued by the registrant, dated July 9, 2003.







                                    SIGNATURE

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  July 10, 2003

                IGEN INTERNATIONAL, INC.

                By:   /s/ George V. Migausky
                      ----------------------
                      Name:       George V. Migausky
                      Title:      Vice President and Chief Financial
                                  Officer (Principal Accounting Officer)